Interleukin-1 receptor antagonist - ImmunoPharmaceutics

Drug Profile

Interleukin-1 receptor antagonist - ImmunoPharmaceutics

Alternative Names: ImmunoPharm IL-1 receptor antagonist

Latest Information Update: 26 Feb 1996

Price : $50

At a glance

  • Originator ImmunoPharmaceutics
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Encephalitis; Gingivitis; Glomerulonephritis; Gout; Inflammation; Psoriasis; Systemic lupus erythematosus

Most Recent Events

  • 26 Feb 1996 Discontinued-Preclinical for Psoriasis in USA (Unknown route)
  • 26 Feb 1996 Discontinued-Preclinical for Encephalitis in USA (Unknown route)
  • 26 Feb 1996 Discontinued-Preclinical for Gingivitis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top